522 related articles for article (PubMed ID: 27542212)
1. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
2. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention.
Wang X; Yao J; Wang J; Zhang Q; Brady SW; Arun B; Seewaldt VL; Yu D
Cancer Prev Res (Phila); 2017 Nov; 10(11):641-650. PubMed ID: 28877935
[TBL] [Abstract][Full Text] [Related]
3. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis.
Faghiri Z; Bazan NG
Exp Eye Res; 2010 Jun; 90(6):718-25. PubMed ID: 20230819
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
6. The novel role of pyrvinium in cancer therapy.
Momtazi-Borojeni AA; Abdollahi E; Ghasemi F; Caraglia M; Sahebkar A
J Cell Physiol; 2018 Apr; 233(4):2871-2881. PubMed ID: 28500633
[TBL] [Abstract][Full Text] [Related]
7. L6 myoblast differentiation is modulated by Cdk5 via the PI3K-AKT-p70S6K signaling pathway.
Sarker KP; Lee KY
Oncogene; 2004 Aug; 23(36):6064-70. PubMed ID: 15208659
[TBL] [Abstract][Full Text] [Related]
8. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
von der Heyde S; Bender C; Henjes F; Sonntag J; Korf U; Beißbarth T
BMC Syst Biol; 2014 Jun; 8():75. PubMed ID: 24970389
[TBL] [Abstract][Full Text] [Related]
9. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
Abraham J
Expert Rev Anticancer Ther; 2015 Jan; 15(1):51-68. PubMed ID: 25306975
[TBL] [Abstract][Full Text] [Related]
11. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
[TBL] [Abstract][Full Text] [Related]
12. Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration.
Qiu Q; Yang M; Tsang BK; Gruslin A
Mol Hum Reprod; 2004 Sep; 10(9):677-84. PubMed ID: 15235105
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
15. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy.
Zhao YW; Jin L; Li ZM; Zhao CJ; Wei YQ; Yang HS
Cancer Sci; 2011 Aug; 102(8):1469-75. PubMed ID: 21561530
[TBL] [Abstract][Full Text] [Related]
19. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
[TBL] [Abstract][Full Text] [Related]
20. Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.
Dattilo R; Mottini C; Camera E; Lamolinara A; Auslander N; Doglioni G; Muscolini M; Tang W; Planque M; Ercolani C; Buglioni S; Manni I; Trisciuoglio D; Boe A; Grande S; Luciani AM; Iezzi M; Ciliberto G; Ambs S; De Maria R; Fendt SM; Ruppin E; Cardone L
Cancer Res; 2020 Oct; 80(19):4087-4102. PubMed ID: 32718996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
